Biogen has arrived at a highly unusual solution to a dispute surrounding a patent for its blockbuster multiple sclerosis drug Tecfidera. It has agreed to pay Denmark’s Forward Pharma $1.25 ...

The risk of disease activity in going to a less effective DMT was higher in younger adults and those having prior ...

Biogen generated nearly $6 billion in MS revenue in 2023, although we see these sales declining nearly 10% annually as the firm faces branded competition, generic pressure on Tecfidera ...

Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...

Biogen’s multiple sclerosis franchise has been handed a boost with the US approval of Vumerity, a follow-up to its blockbuster Tecfidera that promises to be less likely to cause gastrointestinal ...

Voyager Therapeutics’ progress with drug candidates targeting tau marks a step in how the industry is walking multiple paths toward new therapeutic options.

Bringing years of experience and expertise to her most recent appointment, the South Jersey MS Center, Dr. Indrani S.

Learn more about whether Biogen Inc. or Insmed Incorporated is a better investment based on AAII's A+ Investor grades, which ...

Biogen also has a biosimilars segment producing generic drugs with a 4% YoY revenue growth of $202 million in 2024. Tecfidera and Vumerity are treatments for multiple sclerosis (MS). Its MS segment is ...

Multiple sclerosis product decline is obviously driven by a number of factors going forward, including the timing of a TYSABRI biosimilar in the U.S. And timing of TECFIDERA generics in Europe.

High-rolling investors have positioned themselves bullish on Biogen BIIB, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of ...